Name	Current Price - Today's Change	Market Cap
SANOFI-AVENTIS ADS (SNY)	$36.47 - $0.56(1.56%)	93.43 B
ABBOTT LABORATORIES (ABT)	$53.53 - $0.18(0.33%)	83.48 B
ASTRAZENECA PLC (AZN)	$44.30 - $1.17(2.71%)	62.34 B
AMGEN INC (AMGN)	$57.38 - $0.08(0.14%)	58.38 B
TEVA PHARMACEUTICAL LTD (TEVA)	$57.33 - $0.41(0.72%)	51.77 B
GILEAD SCIENCES INC (GILD)	$46.43 - $0.34(0.74%)	41.74 B
ELI LILLY & CO (LLY)	$35.15 - $0.37(1.06%)	39.66 B
NOVO NORDISK A/S (NVO)	$69.86 - $0.72(1.04%)	36.54 B
CELGENE CORP (CELG)	$55.80 - $1.03(1.88%)	25.35 B
ALLERGAN INC (AGN)	$58.98 - $0.81(1.39%)	17.85 B

STOCK ANALYSIS

Downside Risk At Mead Johnson (MJN, BMY, NSRGY, DANOY)
Mead Johnson is the only pure-play option to gain exposure to the stable pediatric nutritional market.

There's Nothing Generic About the Profits (TEVA, WPI)
Any healthcare reform will include severe cost cutting. Giving your portfolio a dose of generic-dug makers will hel...

4 Stocks With Recently Raised Annual Dividends (T, GIS, BMY, BEN)
A raise in dividends is a vote of confidence in current and future earnings.

Adding A Healthy Dose Of Dividends (DVY, MO, SYY, BMY)
Dividends are making a comeback. We look at three of the top yielders for 2010.

A Review Of The Drug Makers Of 2009 (PFE, MRK, BMY)
Corporate deal-making was the name of the big pharma game in 2009 and will likely continue into the new year.

View All Stock Analysis

BMY RELATED HEADLINES

Pfizer Drags Down Pharma
In spite of year-over-year gains, the drugmaker's Q4 earnings and 2010 forecast fell short of expectations.
Forbes.com 2/3/2010

Pfizer Miss Leads Pharma Lower
In spite of year-over-year gains, the drugmaker's Q4 earnings and 2010 forecast fell short of expectations.
Forbes.com 2/3/2010

Downside Risk At Mead Johnson (MJN, BMY, NSRGY, DANOY)
Mead Johnson is the only pure-play option to gain exposure to the stable pediatric nutritional market.
at Investopedia Advisor 2/2/2010

Humana's Disheartening Outlook
Some analysts see upside to EPS growth, but insurer's forecast misses The Street's consensus call.
Forbes.com 2/1/2010

Humana's Healthier Results
Insurer reports bump in Q4 profit despite negative impact of high unemployment rate.
Forbes.com 2/1/2010

Plavix Thickens Bristol-Myers Profit
The drugmaker also benefited from the spin-off of Mead Johnson.
Forbes.com 1/28/2010

View All Headlines